Physician profile
Dmitriy Gen
NPI 1962701227
$3,790.97
in general payments reported to CMS, 2019-2025
30 companies · $611 in 2025
The $611 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $965 · 2020: $251 · 2021: $425 · 2022: $679 · 2023: $405 · 2024: $455 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,471.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $977.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $320.03 | 2020-2023 | Fanapt, Hetlioz |
| Lilly USA, LLC | $273.66 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $257.94 | 2019-2023 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $243.81 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Sanofi Pasteur INC. | $220.99 | 2019-2025 | |
| Abbott Laboratories | $170.89 | 2019-2025 | Triclip |
| Abbvie INC. | $138.55 | 2021-2022 | |
| Pfizer INC. | $120.70 | 2019-2025 | |
| Exact Sciences Corporation | $113.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $85.87 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $84.24 | 2024-2025 | |
| Amgen INC. | $81.46 | 2019-2020 | |
| Radius Health, INC. | $66.41 | 2023 | Tymlos |
| Ardelyx, INC. | $63.03 | 2024 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $62.37 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.42 | 2024-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $58.86 | 2021-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $56.27 | 2019-2021 | |
| Dynavax Technologies Corporation | $52.67 | 2024-2025 | Heplisav-B |
| Hologic Sales and Service, LLC | $50.28 | 2024 | Thinprep 2000 Processor, Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $47.73 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $46.41 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $30.18 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $30.11 | 2023 | Arcalyst |
| Corcept Therapeutics | $18.59 | 2024 | Korlym |
| Nevro Corp. | $17.50 | 2022 | |
| Xeris Pharmaceuticals, INC. | $14.52 | 2024 | Gvoke Hypopen |
| Redhill Biopharma INC. | $14.28 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Gen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.